Need help finding what you are looking for?
Contact Us
PUBLISHER: IMARC | PRODUCT CODE: 1661097
PUBLISHER: IMARC | PRODUCT CODE: 1661097
Idiopathic Pulmonary Fibrosis Treatment Market Report by Drug Class (MAPK Inhibitors, Tyrosine Inhibitors, Autotaxin Inhibitors), End User (Hospitals, Long-term Care Facilities, and Others), and Region 2025-2033
PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
The global idiopathic pulmonary fibrosis treatment market size reached USD 4,103.7 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 7,315.8 Million by 2033, exhibiting a growth rate (CAGR) of 6.3% during 2025-2033.
Idiopathic pulmonary fibrosis (IPF) refers to a progressive and irreversible fibrosing interstitial pneumonia that directly impacts the functioning of the lungs. It is characterized by the formation of scar tissue within the lungs that starts at the edges and progresses toward the center, thus causing difficulties in breathing and insufficient delivery of oxygen to the body parts. It is diagnosed through chest imaging studies, lung biopsies, pulmonary function tests and antibody tests. Two of the most commonly used antifibrotic therapy includes nintedanib and pirfenidone-based drugs, which improves lung functioning and minimizes the risks of acute respiratory deterioration. They are often coupled with oxygen therapy and palliative care to provide comfort and improve the recovery of the patient.
The increasing prevalence of fibrotic diseases, along with the rising geriatric population across the globe, is one of the key factors driving the growth of the market. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products, such as cigarettes, is providing a thrust to the market growth. Moreover, smoking tobacco and cigarettes is considered as one of the most common causes for the development of IPF. In line with this, increasing health consciousness among the masses regarding the effective management strategies of IPF is also favoring the growth of the market. Additionally, the advent of novel medicines and advancements in the IPF diagnostic and treatment methods, are acting as other growth-inducing factors. This, along with extensive research and development (R&D) activities and improvements in the healthcare infrastructure, represents some of the other factors anticipated to drive the market further.
Key Market Segmentation:
Breakup by Drug Class:
- MAPK Inhibitors
- Tyrosine Inhibitors
- Autotaxin Inhibitors
Breakup by End User:
- Hospitals
- Long-term Care Facilities
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being AdAlta Pty Ltd., Angion Biomedica Corp., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche AG (Roche Holding AG), Fibrogen Inc., Galapagos NV, Liminal BioSciences Inc., Medicinova Inc., Merck & Co. Inc., Novartis AG and Vectura Group Plc.
Key Questions Answered in This Report:
- How has the global idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years ?
- What has been the impact of COVID-19 on the global idiopathic pulmonary fibrosis treatment market ?
- What are the key regional markets ?
- What is the breakup of the market based on the drug class ?
- What is the breakup of the market based on the end user ?
- What are the various stages in the value chain of the industry ?
- What are the key driving factors and challenges in the industry ?
- What is the structure of the global idiopathic pulmonary fibrosis treatment market and who are the key players ?
- What is the degree of competition in the industry ?
Product Code: SR112025A2507
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Idiopathic Pulmonary Fibrosis Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Drug Class
- 6.1 MAPK Inhibitors
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Tyrosine Inhibitors
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Autotaxin Inhibitors
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by End User
- 7.1 Hospitals
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Long-term Care Facilities
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 AdAlta Pty Ltd.
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.2 Angion Biomedica Corp.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.3 Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG)
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.4 Bristol-Myers Squibb Company
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Cipla Inc.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 SWOT Analysis
- 13.3.7 Fibrogen Inc.
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.8 Galapagos NV
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.9 Liminal BioSciences Inc.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.10 Medicinova Inc.
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.10.3 Financials
- 13.3.10.4 SWOT Analysis
- 13.3.11 Merck & Co. Inc.
- 13.3.11.1 Company Overview
- 13.3.11.2 Product Portfolio
- 13.3.11.3 Financials
- 13.3.11.4 SWOT Analysis
- 13.3.12 Novartis AG
- 13.3.12.1 Company Overview
- 13.3.12.2 Product Portfolio
- 13.3.12.3 Financials
- 13.3.12.4 SWOT Analysis
- 13.3.13 Vectura Group Plc
- 13.3.13.1 Company Overview
- 13.3.13.2 Product Portfolio
- 13.3.13.3 Financials
- 13.3.13.4 SWOT Analysis
- 13.3.1 AdAlta Pty Ltd.
Product Code: SR112025A2507
List of Figures
- Figure 1: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
- Figure 2: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019-2024
- Figure 3: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2024
- Figure 4: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2024
- Figure 5: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %), 2024
- Figure 6: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 7: Global: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 8: Global: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 9: Global: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 10: Global: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 11: Global: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 12: Global: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 13: Global: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 14: Global: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 15: Global: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 16: Global: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 17: Global: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 18: Global: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 19: North America: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 20: North America: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 21: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 22: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 23: Canada: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 24: Canada: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 25: Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 26: Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 27: China: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 28: China: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 29: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 30: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 31: India: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 32: India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 33: South Korea: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 34: South Korea: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 35: Australia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 36: Australia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 37: Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 38: Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 39: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 40: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 41: Europe: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 42: Europe: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 43: Germany: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 44: Germany: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 45: France: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 46: France: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 47: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 48: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 49: Italy: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 50: Italy: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 51: Spain: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 52: Spain: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 53: Russia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 54: Russia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 55: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 56: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 57: Latin America: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 58: Latin America: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 59: Brazil: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 60: Brazil: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 61: Mexico: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 62: Mexico: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 63: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 64: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 65: Middle East and Africa: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
- Figure 66: Middle East and Africa: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 67: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
- Figure 68: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
- Figure 69: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2024 and 2033
- Table 2: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
- Table 3: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million USD), 2025-2033
- Table 4: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
- Table 5: Global: Idiopathic Pulmonary Fibrosis Treatment Market Structure
- Table 6: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.